Mode
Text Size
Log in / Sign up
Phase 3 N=201 Randomized Double-blind Prevention

Risk of Oxygen During Cardiac Surgery Trial

Cardiac Surgery

Enrolled (actual)
201
Serious AEs
9.5%
Results posted
Aug 2023
Primary outcome: Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Oxygen - normoxia (Drug); Oxygen - hyperoxia (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Vanderbilt University
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Intraoperative Systemic Oxidative Damage
69; 83
PRIMARY
Acute Kidney Injury
-0.01; 0.01
SECONDARY
Vascular Reactivity / Endothelial Function (as Measured by Flow Mediated Dilation)
4.50; 4.71
SECONDARY
Mitochondrial Function
1884; 1936
SECONDARY
Number of People With Arrhythmia
37; 46
SECONDARY
Myocardial Injury or Infarction
27.2; 24.5
SECONDARY
Number of People With Stroke
1; 2
SECONDARY
Postoperative Cognitive Dysfunction
3; 2
SECONDARY
Respiratory Failure
5; 1
SECONDARY
Chronic Kidney Disease
63.0; 60.4
SECONDARY
Inflammation
31.08; 36.62
SECONDARY
Hemolysis
388,030; 433,274
SECONDARY
Reactive Oxygen Species Production
17,300; 17,040
SECONDARY
Acute Brain Dysfunction (Delirium)
16; 22
SECONDARY
Oxygenation and Perfusion (Lactate)
1.5; 1.8
SECONDARY
Acute Kidney Injury, According to KDIGO Criteria
21; 21
SECONDARY
Acute Kidney Injury Estimated by Urine Concentration of TIMP-2 IGFBP7
0.224; 0.187
SECONDARY
Acute Kidney Injury Estimated by Urine Concentration of NGAL
6.9; 4.8
SECONDARY
Reactive Oxygen Species Production
17,300; 17,040
SECONDARY
Oxygenation and Perfusion (SpO2)
97; 100
SECONDARY
Oxygenation and Perfusion (PaO2)
99; 377
SECONDARY
Oxygenation and Perfusion (Cerebral Oximetry)
-7.2; 6.0
SECONDARY
Oxygenation and Perfusion (SvO2)
68; 78
SECONDARY
Oxygenation and Perfusion (Cardiac Index)
2.56; 2.48
SECONDARY
Vascular Reactivity / Endothelial Function (Peripheral Artery Tonometry)
1.41; 1.23
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, EC50)
-6.13; -5.92
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, Emax)
36.2; 39.5
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, EC50)
-6.95; -5.75
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, Emax)
91.5; 92.6
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, EC50)
-6.89; -6.66
SECONDARY
Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, Emax)
97.1; 96.0
SECONDARY
Vascular Reactivity / Endothelial Function (PAI-1)
31.2; 36.6
SECONDARY
Vascular Reactivity / Endothelial Function (E-selectin)
16.4; 16.2

Summary

The investigators will recruit and randomize 200 elective cardiac surgery patients to receive physiologic oxygenation (normoxia) or hyper-oxygenation (hyperoxia) during surgery to test the hypothesis that intraoperative physiologic oxygenation decreases the generation of reactive oxygen species, oxidative damage, and postoperative organ injury compared to hyper-oxygenation.

Eligibility Criteria

Inclusion Criteria

  • Open-heart cardiac surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy.

Exclusion Criteria

  • Current acute coronary syndrome (defined as ST elevation myocardial infarction or non-ST elevation myocardial infarction (troponin leak within 72 hours of surgery or consent +/- EKG changes consistent with myocardial ischemia)).
  • Home supplemental oxygen use.
  • Preoperative supplemental oxygen requirement to maintain arterial O2 sat of 92%.
  • Right to left intracardiac shunt including atrial septal defect and ventricular septal defect with Cor Pulmonale.
  • Carotid stenosis defined as >50% stenosis.
  • Cardiac surgery that requires intraoperative circulatory arrest, such as aortic arch replacement.
  • Current use of hemo- or peritoneal dialysis.
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02361944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search